Apnimed, Inc. (NASDAQ:APMD) Stock Has Consensus Target Price of $50.33

Apnimed, Inc. (NASDAQ:APMD) has been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $50.33.

A number of equities analysts have weighed in on APMD shares. Cantor Fitzgerald assumed coverage on Apnimed in a research note on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price objective for the company. Lifesci Capital started coverage on Apnimed in a report on Tuesday, August 25th. They set an “outperform” rating and a $50.00 target price on the stock. Evercore began coverage on Apnimed in a research report on Tuesday, August 25th. They set an “outperform” rating for the company. Zacks Research upgraded Apnimed to a “hold” rating in a research report on Wednesday, August 26th. Finally, Wall Street Zen raised Apnimed to a “hold” rating in a report on Saturday, August 8th.

Apnimed Stock Performance

Shares of Apnimed stock opened at $15.81 on Wednesday. The stock has a market capitalization of $658.17 million and a PE ratio of 6.01. The business’s fifty day simple moving average is $21.16. Apnimed has a 1 year low of $13.88 and a 1 year high of $35.29.

Apnimed (NASDAQ:APMD) last posted its quarterly earnings results on Tuesday, September 8th. The company reported $0.51 EPS for the quarter. The business had revenue of $12.08 million during the quarter. On average, analysts predict that Apnimed will post -0.24 earnings per share for the current fiscal year.

Apnimed Company Profile

Apnimed is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies. Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment.